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Abstract 17 
Delayed pubertal onset has many etiologies, but on average two-thirds of patients 18 
presenting with late puberty have self-limited (or constitutional) delayed puberty. Self-limited 19 
delayed puberty often has a strong familial basis. Segregation analyses from previous studies 20 
show complex models of inheritance, most commonly autosomal dominant, but also 21 
including autosomal recessive, bilineal and X-linked. Sporadic cases are also observed. 22 
Despite this, the neuroendocrine mechanisms and genetic regulation remain unclear in the 23 
majority of patients with self-limited delayed puberty.  24 
Only rarely have mutations in genes known to cause aberrations of the hypothalamic-25 
pituitary-gonadal axis been identified in cases of delayed puberty, and the majority of these 26 
are in relatives of patients with congenital hypogonadotropic hypogonadism (CHH), for 27 
example in the FGFR1 and GNRHR genes. Using next generation sequencing in a large 28 
family with isolated self-limited delayed puberty, a pathogenic mutation in the CHH gene 29 
HS6ST1 was found as the likely cause for this phenotype. Additionally, a study comparing 30 
the frequency of mutations in genes that cause GnRH deficiency between probands with 31 
CHH and probands with isolated self-limited delayed puberty identified that a significantly 32 
higher proportion of mutations with a greater degree of oligogenicity were seen in the CHH 33 
group. 34 
Mutations in the gene IGSF10 have been implicated in the pathogenesis of familial 35 
late puberty in a large Finnish cohort. IGSF10 disruption represents a fetal origin of delayed 36 
puberty, with dysregulation of GnRH neuronal migration during embryonic development 37 
presenting for the first time in adolescence as late puberty. Some patients with self-limited 38 
delayed puberty have distinct constitutional features of growth and puberty. Deleterious 39 
variants in FTO have been found in families with delayed puberty with extremely low BMI 40 
and maturational delay in growth in early childhood. Recent exciting evidence highlights the 41 
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importance of epigenetic up-regulation of GnRH transcription by a network of miRNAs and 42 
transcription factors, including EAP1, during puberty.  43 
Whilst a fascinating heterogeneity of genetic defects have been shown to result in 44 
delayed and disordered puberty, and many are yet to be discovered, genetic testing may 45 
become a realistic diagnostic tool for the differentiation of conditions of delayed puberty. 46 
  47 
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Introduction 48 
The timing of puberty in humans and other mammals is strongly influenced by genetic 49 
regulation. Studies using epidemiological and intra-familial tools give an estimate of 50-80% 50 
of the variation in timing of pubertal onset being under genetic control (Morris et al., 2011, 51 
Eaves et al., 2004). Another illustration of this is the high correlation of the timing of sexual 52 
maturation observed between twins (van den Berg et al., 2006). Although the precise age of 53 
onset of puberty varies within and between different populations, it is a highly heritable 54 
phenotypic feature (Palmert and Boepple, 2001). Despite this strong genetic component, 55 
there is much that we still do not understand about the physiological control of the timing of 56 
onset of, or progression through, puberty (DiVall and Radovick, 2008). 57 
The clinical phenotype of delayed puberty can be a feature of several different 58 
conditions (Palmert and Dunkel, 2012). However, the most common presentation is with 59 
isolated and self-limited delayed puberty (also known as constitutional delay of growth and 60 
puberty, or CDGP). Self-limited delayed puberty has been shown in several observational 61 
studies to be the commonest cause of delayed puberty in males and females (Abitbol et al., 62 
2016). More than 80% of boys and around one-third of girls presenting with late pubertal 63 
onset have this disorder of pubertal timing. The term ‘self-limited’ has been coined as in 64 
these patients puberty will have commenced by the age of 18 years. Notably, constitutional 65 
features involving short stature or slow growth in early childhood are not seen in all patients 66 
with ‘simple’ delayed puberty. In a patient presenting with delayed puberty in adolescence 67 
there are three main differential diagnoses: 1) central hypogonadism which is functional or 68 
temporary, where inhibition of the hypothalamic-pituitary-gonadal (HPG) axis is secondary 69 
to chronic disease (in one-fifth of those with late pubertal onset), under-nutrition, excessive 70 
exercise, or psychological distress; 2) permanent (central) hypogonadotropic hypogonadism, 71 
either congenital hypogonadotropic hypogonadism (CHH) or acquired, with classically low 72 
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or normal LH and FSH levels (seen in 9% of males and up to one-fifth% of females); and 3) 73 
primary hypogonadism, with elevated gonadotropin levels secondary to gonadal failure, low 74 
sex steroid concentrations and failure of negative feedback (in approximately 7% of males 75 
and one-quarter of females with late pubertal onset) (Sedlmeyer, 2002a). 76 
Self-limited delayed puberty represents a timing of puberty onset at the extreme end 77 
of normal. Thus, those patients with this condition have a lack of testicular enlargement in 78 
males or breast development in females at an age that is 2 to 2.5 standard deviations (SD) 79 
later than the population mean (Figure 1) (Palmert and Dunkel, 2012). Moreover, children 80 
with slow or stuttering progression through puberty, as diagnosed through the use of puberty 81 
normograms, can also fall within this diagnostic category (Lawaetz et al., 2015) (Figure 1). 82 
Delay of pubertal development has now been recognized to be associated with several long-83 
term sequelae and is no longer seen as a benign developmental variant (Zhu and Chan, 2017). 84 
These adverse consequences include a higher risk for early natural menopause and poor 85 
overall health (Day et al., 2015) and negatively affected psychosocial well-being and peer 86 
relationships (Albanese and Stanhope, 1995). There is some evidence that delayed puberty is 87 
associated with lower bone density (Parker et al., 2014). Adult height can be affected by late 88 
pubertal timing but on average it is only slightly below the genetic target (Albanese and 89 
Stanhope, 1995).  90 
Between half and two-thirds of those patients with self-limited delayed puberty have a 91 
family history of late puberty (Sedlmeyer, 2002b). Observational studies have demonstrated 92 
that self-limited delayed puberty is inherited with several different inheritance patterns 93 
including autosomal dominant or recessive, bilineal (both parents affected by delayed 94 
puberty) and X-linked. Sporadic cases are also observed (Figure 2). However, the majority of 95 
families display an autosomal dominant pattern of inheritance (with or without complete 96 
penetrance) (Howard and Dunkel, 2017, Sedlmeyer, 2002b, Wehkalampi et al., 2008b). 97 
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Whilst previously considered to be more common in males, evidence suggests that self-98 
limited delayed puberty is not sex-specific, as within families there are near equal ratios of 99 
males and females affected with the trait (Wehkalampi et al., 2008b). Indeed, in a cohort 100 
review by Winter et al, there were a higher number of female than male relatives affected 101 
with delayed puberty (47 females vs 34 males) (Winter et al., 2016). The higher number of 102 
males that present to a medical team may well be a consequence of referral bias. 103 
The etiology is unknown in the majority of patients with delayed puberty (Cousminer 104 
et al., 2015, Wehkalampi et al., 2008a). Identification of causal genetic defects in familial 105 
delayed puberty is complex for a numbers of reasons. Firstly, delayed puberty is not a rare 106 
condition, occurring (by statistical definition) in approximately 2% of the population. 107 
Secondly, whilst some pedigrees display clear Mendelian inheritance patterns it is likely that 108 
patients may have a di- or oligogenic (where variants in more two genes contribute to the 109 
phenotype) genetic basis for their phenotype in many cases. Thirdly, as noted above, self-110 
limited delayed puberty represents a timing of puberty onset at the extreme end of a near-111 
normally distributed trait in the general population, so there may be a low level of causal 112 
variants for this condition seen in population databases. Therefore, we cannot, as is often 113 
applied for rare diseases, filter out all non-novel variants from our sequencing datasets when 114 
searching for causal variants. Instead, we need to compare the prevalence of all rare and 115 
predicted damaging variants in a certain gene between cases and controls, in order to identify 116 
those genes that are enriched for deleterious variants in patients compared to the general 117 
population (Guo et al., 2018). Finally, the impact of environmental factors such as nutrition 118 
and endocrine disruptors superimposed on genetic regulation can ‘muddy the waters’ for 119 
those attempting to isolate definitive genetic causes of delayed puberty. 120 
 121 
Overlap with common genetic variants of pubertal timing 122 
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 Leptin and its pathways: The noted secular trend towards an earlier age of pubertal 123 
onset in the developed world has been a subject of study for some time. The importance of 124 
energy balance and over- or under-nutrition is clear; a minimum level of energy availability 125 
is needed for puberty to ensue, but in contrast higher BMI is associated with earlier puberty 126 
(Wang, 2002) Ref Wang 2002 Pediatrics. This latter statement has been seen especially in 127 
females (Sorensen et al., 2010, He and Karlberg, 2001), but the underlying patho-biology is 128 
still not entirely clear.  Leptin, a key metabolic hormone and modulator of BMI in humans, is 129 
produced from white adipose tissue (Figure 3). It is a major signal of energy sufficiency and 130 
mediates, at least in part, the influence of fat mass on pubertal timing. Leptin is a permissive 131 
signal for puberty and is necessary for normal reproduction. In females, serum leptin 132 
concentrations rise at the onset of puberty (Ahmed et al., 1999). Both humans and mice 133 
which lack leptin (Lep ob/ob) or its receptor (LepR db/db) show failure to complete puberty 134 
and are infertile (Farooqi, 2002). However, leptin is not the key coordinator in the up-135 
regulation of GnRH signaling pathways at pubertal onset. Leptin alone does not stimulate 136 
pubertal onset and, whilst in females leptin concentrations rise during puberty, levels are 137 
lower in males and decrease during puberty (Garcia-Mayor et al., 1997). GnRH neurons do 138 
not express LepR therefore leptin cannot act directly to regulate GnRH neurons. Instead its 139 
acts indirectly via leptin-sensitive afferents which project to GnRH neurons (Elias and 140 
Purohit, 2013). These afferents are likely to include LEPR-expressing GABA neurons from 141 
the arcuate nucleus, nitric oxide (which is required for its action) pathways, mTOR signaling, 142 
as well as kisspeptin/ neuropeptide Y neurons (Roa and Tena-Sempere, 2010, Bellefontaine 143 
et al., 2014).  144 
Genome-wide Association Studies: A key strategy in the attempt to uncover the key 145 
genetic regulators of pubertal timing in the general population has been genome-wide 146 
association studies (GWAS) of age at menarche and voice-breaking in healthy women and 147 
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men respectively. The first locus to be identified as associated with pubertal timing was the 148 
single nucleotide polymorphism (SNP) rs314276 in the gene LIN28B (Ong et al., 2009). The 149 
major allele of this SNP correlates with earlier breast development and menarche in girls 150 
(Ong et al., 2009). LIN28B is a human orthologue of a Caenorhabditis elegans gene important 151 
for developmental timing. The lin-28 family regulates, and is regulated by, the let-7 family of 152 
microRNAs (miRNAs). However, no human mutations in LIN28B have been identified, 153 
neither with delayed (Tommiska et al., 2010) nor with early puberty (Silveira-Neto et al., 154 
2012).  155 
Since this initial discovery several increasingly large meta-analyses have been carried 156 
out on GWAS of timing of puberty. Whilst the first of these identified 42 (30 new, 2 157 
previously confirmed and 10 possible) loci for age at menarche (Elks et al., 2010), an 158 
analysis of 182,416 European women encompassing 57 studies (Perry et al., 2014) identified 159 
106 genomic loci. These meta-analyses are ongoing, but the largest to date which comprises 160 
1000 Genomes Project-imputed genotype data in approximately 370,000 women has isolated 161 
389 independent signals (P < 5 × 10-8) for age at menarche (Day et al., 2017). The effect size 162 
of each of these alleles on the timing of menarche is between 1 week and five months. In total 163 
the loci identified in this study can explain ∼7.4% of the variation in the timing of menarche 164 
in the general population, which corresponds to approximately 25% of the estimated 165 
heritability. Together this data suggests that individually many of these genetic variants have 166 
a low impact in the general population (Day et al., 2017). Hence these huge studies suggest 167 
that there is a large degree of heterogeneity in the genetic determinants of normal pubertal 168 
timing. A large number of these signals show a significant association with Tanner staging in 169 
men and women, implying that the data is applicable to both genders. Additionally, many of 170 
these signals have been shown to have concordant effects on the age at voice breaking. 171 
However, in women the signals identified have stronger effects on early than on late age of 172 
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menarche, but in contrast have larger effect estimates for relatively late than relatively early 173 
voice breaking in males (Day et al., 2017). 174 
Multiple signals in or near genes regulating the HPG axis function have been found 175 
by these studies including LEPR-LEPROT, GNRH1 and TACR3, mutations in which have 176 
been shown to be causal in CHH (Farooqi et al., 2007, Silveira et al., 2010). Loci in or near 177 
several further genes related to development of the pituitary and its function were also seen, 178 
including POU1F1, TENM2 and LGR4, the last of which acts as an enhancer for the pituitary 179 
development factor SOX2.  180 
Energy metabolism genes found by GWAS: In addition to leptin signaling, several 181 
other genes implicated in body mass index including FTO, SEC16B, TMEM18, and NEGR1 182 
have been implicated by GWAS as having a role in the timing of puberty. FTO had already 183 
been identified via GWAS of susceptibility to obesity, and it remains the original and most 184 
impactful locus with respect to effect on BMI and risk of obesity (Yeo, 2014). Subsequently, 185 
using next generation sequencing techniques rare heterozygous variants in FTO have been 186 
identified in pedigrees with self-limited delayed puberty associated with extreme low BMI 187 
and maturational delay in growth in early childhood (Howard et al., 2018a). In a parallel 188 
murine experiment, mice that were heterozygous for FTO gene knockout were shown to have 189 
significantly delayed timing of puberty (Howard et al., 2018a).  190 
A further gene, IRX3, identified at the same GWAS locus as FTO, was later found 191 
also to be of importance in influencing BMI (Smemo et al., 2014); however the evidence 192 
from animal models on the effect of FTO on food intake regulation remains robust 193 
(McMurray et al., 2013), although its actions may be complex (Merkestein et al., 2015). 194 
FTO-knockout mice (Fischer et al., 2009) and in vitro studies have demonstrated that 195 
essential amino acids act to modulate the expression of FTO and that FTO acts downstream 196 
to influence mTORC1 signaling (Speakman, 2015). mTOR acts as a coupler of energy 197 
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balance and the activity of the reproductive axis by regulation of the hypothalamic expression 198 
of the kisspeptin gene (Martinez de Morentin et al., 2014). Blockade of mTOR in a rodent 199 
model led to delayed vaginal opening with blunting of the positive effects of leptin on 200 
puberty onset in food-restricted females (Roa et al., 2009). However, it is still unknown if the 201 
effect of FTO on pubertal timing is facilitated via effects on BMI, via mTOR signaling, or by 202 
both.  203 
Other energy metabolism genes: Neuropeptide Y (NPY) is another protein implicated 204 
in the regulation of food intake and satiety, as well as the hypothalamic-pituitary axis. NPY 205 
increases the response of pituitary gonadotrope cells to GnRH (Parker et al., 1991), both by 206 
stimulating GnRH binding to pituitary GnRH receptors and by its action upstream at the 207 
median eminence to potentiate GnRH secretion from GnRH axon terminals (Crowley and 208 
Kalra, 1987). Studies with primate models imply that NPY may contribute to the brake that 209 
restrains the onset of puberty between infancy and mid-childhood (Plant, 2015). The link 210 
between energy homeostasis and reproductive development may also be mediated by ghrelin 211 
and other gut-derived peptides (Couce et al., 2006, Pomerants et al., 2006a, Pomerants et al., 212 
2006b). α-MSH signaling via MC3/4 receptors, acting to increase Kiss1 expression and 213 
mediate the permissive effects of leptin on puberty, has also been implicated recently as an 214 
important element in the metabolic control of puberty (Manfredi-Lozano et al., 2016). Lastly, 215 
mice lacking the insulin receptor in astrocytes have delayed puberty and irregular estrus 216 
cycles, with reduced astrocyte prostaglandin E synthase 2 levels (Manaserh et al., 2019). 217 
However, roles for the majority of these genes involved in fat mass and metabolic regulation 218 
have not been demonstrably shown in human delay of puberty. A small cohort of 31 patients 219 
was analyzed for mutations in the ghrelin receptor, or GHSR, and 5 patients were found to 220 
have point mutations in this gene (Pugliese-Pires et al., 2011).  221 
 222 
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Importance of GnRH neuroendocrine network in the pathogenesis of delayed puberty 223 
Overlap between GnRH deficiency and delayed puberty: It is biologically very 224 
plausible that the pathophysiology of delayed puberty and conditions of GnRH and 225 
gonadotropin deficiency share a common genetic basis. Therefore, investigations have been 226 
carried out into the role of genes known to cause CHH in the phenotype of isolated delayed 227 
puberty. Previous studies in CHH cohorts have found mutations in HS6ST1, FGFR1 and 228 
recently in KLB, not only in small numbers of patients with CHH but also in their relatives 229 
with delayed puberty (Tornberg et al., 2011, Pitteloud et al., 2006, Xu et al., 2017). Last year, 230 
a study was completed that aimed to compare the frequency with which mutations in genes (n 231 
= 24) known to cause GnRH or gonadotropin deficiency were found in patients with CHH 232 
and individuals with self-limited delayed puberty. This comparison found a significantly 233 
higher proportion of mutations in the CHH group (51% of CHH probands vs 7% of delayed 234 
puberty probands, p=7.6x10-11). Whilst this is perhaps unsurprising, a greater degree of 235 
oligogenicity in these GnRH deficiency genes was also seen in the CHH group, suggesting a 236 
mostly distinct or as yet undiscovered genetic basis of these two conditions (Cassatella et al., 237 
2018). Mutations in Kallmann Syndrome (KS) genes such as ANOS1 and NSMF, leading to 238 
hypogonadotropic hypogonadism with anosmia, have not been found in individuals with self-239 
limited pubertal delay.   240 
Studies using next generation sequencing to examine cohorts of patients with delayed 241 
puberty have identified variants in several CHH genes, particularly GNRHR, TAC3 and its 242 
receptor TACR3, but also in IL17RD and SEMA3A (Zhu et al., 2015). However, these variants 243 
have not been tested in vitro or in vivo for pathogenicity, or investigated for within pedigree 244 
segregation. Many syndromic conditions have delayed or absent puberty within the 245 
phenotypic spectrum of the condition, see Table 1.  246 
 247 
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Syndrome Phenotype  Genetic defect 
Prader-Willi (Emerick and 
Vogt, 2013) 
Mental retardation, morbid obesity, 
hypotonia, hypogonadism, growth 
hormone deficiency, hypothyroidism 
Deletions within the 
paternally imprinted 15q 
11.2-12 region 
Bardet-Biedl (Forsythe 
and Beales, 2013) 
 
Mental retardation, obesity, retinitis 
pigmentosa, post-axial polydactyly, 
delayed puberty and hypogonadism 
BBS-1-11 (multiple loci) 
20p12, 16q21, 15q22.3-23, 
14q32.1 
CHARGE anomaly 
(Dauber et al., 2010) 
Coloboma, heart malformations, choanal 
atresia, growth retardation, genital 
anomalies and ear anomalies, 
hypogonadotropic hypogonadism, 
olfactory bulb aplasia, or hypoplasia 
CHD7 
Adrenohypoplasia 
Congenita (Loureiro et al., 
2015) 
Primary adrenal deficiency and 
hypogonadotropic hypogonadism 
NR0B1 
Septo-optic dysplasia 
(Nagasaki et al., 2017) 
Small, dysplastic pale optic discs, 
pendular nystagmus, Midline 
hypothalamic defect with DI, single or 
multiple pituitary hormone deficiency, 
absent septum pellucidum 
HESX1 
Solitary median maxillary 
incisor syndrome 
(Szakszon et al., 2012) 
Prominent midpalatal ridge, 
holoprosencephaly, pituitary defects 
 
SHH  
 
Borjeson-Forssman-
Lehmann syndrome 
(Turner et al., 2004) 
Mental retardation, gynaecomastia, 
moderate short stature, truncal obesity 
PHF6 
Hartsfield (Simonis et al., 
2013) 
Holoprosencephaly, ectrodactyly/ split 
hand and foot malformations, cleft lip 
and palate, hypogonadotropic 
hypogonadism 
FGFR1 
Gordon Holmes 
(Wortmann et al., 2015) 
 
Cerebellar ataxia, dementia, 
chorioretinopathy, anterior 
hypopituitarism 
RNF216/OTUD4 
PNPLA6 
Table 1 – Genetic syndromes associated with pubertal delay 249 
 250 
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Heparin sulphate 6O sulphotransferase 1: Recently, using whole and targeted exome 251 
analysis a mutation in HS6ST1 was found in one extended pedigree from a large cohort of 252 
patients with isolated familial delayed puberty, for the first time without associated CHH in 253 
patient relatives (Howard et al., 2018b). All of the six family members in three generations 254 
that carried the mutation had a classical self-limited delayed puberty phenotype, with no 255 
individuals displaying CHH. A spontaneous onset of puberty was seen in the proband at 14.3 256 
years. A mouse heterozygous knockout model was also examined in parallel. This work 257 
substantiated that loss of one allele of Hs6st1 can provoke pubertal delay but with normal 258 
adult reproductive capacity. The Hs6st1+/− mice displayed no compromise in their fertility, 259 
GnRH neuron or testes development or spermatogenesis and were born at normal Mendelian 260 
ratios. However female mice were seen to have a significant delay in the timing of vaginal 261 
opening, a surrogate for onset of puberty in female rodents.  262 
Notably the Hs6st1+/- mice had no defects of olfactory bulb morphology and no 263 
significant reduction in the total number of GnRH neurons in the hypothalamus or extending 264 
to the median eminence to explain the pubertal delay. Instead, this might be mediated by 265 
changes in either GnRH neuron activity or other relevant downstream pathways, implied by 266 
the expression of Hs6st1 mRNA in both the arcuate nucleus and paraventricular nucleus 267 
(Parkash et al., 2015, Pielecka-Fortuna et al., 2008). These results indicate whilst, as above, 268 
many patients with familial self-limited delayed puberty do not carry mutations in CHH 269 
genes, perturbations in a single allele of a particular subset of genes that modulate the HPG 270 
axis may be enough to result in a phenotype of self-limited pubertal delay. In contrast, more 271 
deleterious alterations in these genes, mutations in both alleles of a gene or a heterozygous 272 
mutation in combination with mutations in further genes, are needed to produce the more 273 
severe phenotypes of CHH and KS (Pitteloud et al., 2007). 274 
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Immunoglobulin Superfamily Member 10: A further study utilizing whole and 275 
targeted exome sequencing methods in the same large Finnish cohort of individuals with 276 
familial self-limited delayed puberty, identified deleterious mutations in the IGSF10 gene in 277 
six unrelated families (Howard et al., 2016). Mutations in this gene affect the migration of 278 
GnRH neurons from the vomeronasal organ in the nose to the forebrain during embryonic 279 
development (Figure 4). The patients with these mutations presented in adolescence with 280 
pubertal delay without features of constitutional delay in growth. Given that a functional 281 
GnRH neurosecretory network is required for the onset of puberty, the hypothesis produced 282 
from this work is that disruption of GnRH neuronal migration, as caused by aberrant IGSF10 283 
signaling, could result in arrival of fewer (or delayed) GnRH neurons at the hypothalamus. 284 
This would then in turn lead to a functional defect in the GnRH neuroendocrine network and 285 
an increased “threshold” for the onset of puberty, with a resultant delay. In addition, loss-of-286 
function mutations in IGSF10 were found in patients with a hypothalamic amenorrhea-like 287 
phenotype, implying a shared genetic basis of functional central hypogonadism with both 288 
CHH (Caronia et al., 2011) and delayed puberty. However, although deleterious mutations 289 
were enriched in CHH patients, there was lack of complete segregation with trait in these 290 
permanent hypogonadotropic hypogonadism families, suggesting that haploinsufficiency of 291 
IGSF10 is not sufficient to cause this phenotype. Interesting, mutations in IGSF10 have very 292 
recently also been found in patients with both premature ovarian insufficiency and disorders 293 
of neuronal development, and in the same report in a further pedigree with a Kallmann-like 294 
phenotype (Jolly et al., 2019). The results of the studies on HS6ST1 and IGSF10 in delayed 295 
puberty point to a mechanism by which developmental defects in the GnRH system during 296 
fetal life can modulate the timing of pubertal onset in adolescence, seemingly without other 297 
phenotypic features. It remains to be determined whether these patients have any deficiency 298 
of the their long-term reproductive capacity or sexual lifespan. 299 
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Genes downstream of GnRH: Autosomal recessive CHH is most frequently caused by 300 
loss-of-function mutations within the GnRH receptor, accounting for 16% to 40% of this 301 
patient group. Mutations have been found within the extracellular, transmembrane and 302 
intracellular domains of the receptor leading to impaired GnRH action (Chevrier et al., 2011). 303 
Sequencing studies that have analyzed the GNRHR gene in cohorts with self-limited delayed 304 
puberty (Chevrier et al., 2011), have found just a handful of deleterious mutations. A 305 
homozygous partial loss-of-function mutation in GNRHR was found in two brothers, one 306 
with self-limited delayed puberty and one with CHH (Lin et al., 2006), and a further 307 
heterozygous mutation found in one male with self-limited delayed puberty (Vaaralahti et al., 308 
2011). Far more rarely defects of the glycoprotein hormones luteinizing hormone (LH) or 309 
follicle-stimulating hormone (FSH) can lead to CHH, in particular via mutations in the 310 
specific β-subunits (Themmen and Huhtaniemi, 2000, Potorac et al., 2016). In women, loss-311 
of-function mutations of LHβ result in normal or late timing of menarche (following a 312 
normally timed onset of puberty) but with later infertility resulting from lack of ovulation 313 
(Lofrano-Porto et al., 2007). In men, similar defects lead to a presentation with absent 314 
pubertal development secondary to Leydig cell hypoplasia resulting in testosterone 315 
deficiency and failure of spermatogenesis. Women with inactivating FSHβ mutations display 316 
pubertal arrest and primary amenorrhea whilst men have a similar pattern of spontaneous 317 
entry into puberty followed by arrest with azoospermia (Layman et al., 1997). Defects in 318 
these two genes do not usually present with a classical picture of self-limited delayed 319 
puberty. 320 
Overall, from the evidence we have from current published work we can conclude 321 
that although there are some shared gene defects, the genetic basis of CHH and delayed 322 
puberty is likely to be due to different, currently unrecognized, genes in many cases (Table 2) 323 
(Vaaralahti et al., 2011).  324 
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 326 
 327 
Table 2 – Non-syndromic Genetic defects associated with pubertal delay 328 
 329 
Phenotype  Gene 
Self-Limited Delayed Puberty, 
Hypogonadotropic Hypogonadism 
HS6ST1 (Howard et al., 
2018b)  
TAC3 (Zhu et al., 2015), 
TACR3 (Zhu et al., 2015), 
IL17RD (Zhu et al., 2015), 
GNRHR (Vaaralahti et al., 
2011) 
SEMA3A (Zhu et al., 2015) 
Self-Limited Delayed Puberty, 
Hypothalamic amenorrhea 
IGSF10 (Howard et al., 
2016) 
Self-Limited Delayed Puberty EAP1 (Mancini et al., 2019) 
Constitutional Delay in Growth and 
Puberty  
FTO (Howard et al., 2018a) 
 330 
However there is a wide spectrum of phenotypes in patients with central hypogonadism, 331 
ranging from complete hypogonadotropic hypogonadism, with failure of pubertal 332 
development, to partial hypogonadism with an arrest of pubertal development, and even 333 
reversible hypogonadotropic hypogonadism in some patients post treatment (Hutchins et al., 334 
2016, Sarfati et al., 2015, Sarfati et al., 2010, Raivio et al., 2007). It may be a prudent 335 
strategy for clinicians to focus the use of genetic testing of known CHH genes in delayed 336 
puberty patients on those patients with either extreme delayed puberty, clear familial 337 
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inheritance or red flags (such as micropenis, cryptorchidism, anosmia, cleft lip or palate or 338 
renal agenesis) which would point to a syndromic or CHH phenotype. 339 
 340 
Transcriptional and epigenetic control of GnRH signaling 341 
The GnRH pulse generator: The central control of pubertal onset, after the mid-342 
childhood period of HPG axis quiescence, is orchestrated by a resurgence of the GnRH pulse 343 
generator, with a reduction in central inhibition and a sharp upregulation in the activity of this 344 
axis. This activity is permitted by a change in the balance of GABA-glutamate signaling in 345 
the brain (Bourguignon et al., 1997). Around this time morphological changes in GnRH 346 
neurons have been observed including increases in dendritic spine density and a 347 
simplification of their dendritic architecture. The intensification of kisspeptin signaling in the 348 
hypothalamus, one of the key hormonal players in puberty onset, at this time is a 349 
consequence of both an increase of kisspeptin synthesis and a rise in the responsiveness of 350 
GnRH neurons to kisspeptin stimulation. This mechanism has been well observed in murine 351 
models, but also in primates and is relatively conserved during evolution (Plant and Barker-352 
Gibb, 2004). However, what is far less well understood are what the triggers are for this 353 
upregulation of kisspeptin biosynthesis in the hypothalamus at the end of the juvenile period. 354 
Thus, whilst there is strong evidence that the secretion of kisspeptins from KNDy neurons in 355 
the arcuate nucleus is one of the vital stimulatory inputs on the GnRH pulse generator, it is 356 
not likely to be the ultimate controller of the release of the puberty brake. Rather, kisspeptin 357 
is the conductor of the orchestra of upstream stimulators and repressors influencing the 358 
system at this crucial developmental stage (Plant, 2015). 359 
Transcriptional control of the GnRH network: It is likely, therefore, that there is no 360 
one single gene that is capable of the hypothalamic control of puberty onset. Instead, we can 361 
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imagine a hierarchical network of genes acting together to lift the brake applied during the 362 
dormancy of the HPG axis in mid-childhood (Figure 3). Data to support this hypothesis have 363 
largely come from a systems biology approach (Ojeda et al., 2010) and animal models (Plant, 364 
2015), with little data from human subjects. It is clear that transcriptional repression is 365 
fundamentally important to the regulation of gene expression in mammals.  Transcriptional 366 
repressors containing zinc finger motifs, which recognize specific DNA sequences in 367 
regulatory regions of the genome, are particularly appealing candidates to have major roles in 368 
this governing network (Lomniczi et al., 2015). Potential key regulators include Oct-2, Ttf-1, 369 
Yy1 and Eap1. Oct-2 is a transcriptional regulator of the POU-domain family of homeobox-370 
containing genes. Oct-2 mRNA is upregulated in the hypothalamus in juvenile rodents; 371 
blockage of Oct-2 synthesis delays age at first ovulation and hypothalamic lesions which 372 
induce precocious puberty (e.g. hamartomas) activate Oct-2 expression (Ojeda et al., 1999). 373 
Ttf-1 is another homeobox gene that enhances GnRH expression (Mastronardi et al., 2006). 374 
Ttf-1 expression is increased in pubertal rhesus monkeys (Lee et al., 2001). Yy1 is a zinc-375 
finger transcription factor with crucial roles in normal development and malignancy 376 
(Gabriele et al., 2017). Eap1, or Enhanced at puberty 1, codes for a nuclear transcription 377 
factor, characterized by a dual transcriptional activity: it both trans-activates the GnRH 378 
promoter, which facilitates GnRH secretion, and inhibits the preproenkephalin promoter, 379 
which represses GnRH secretion. Eap1 mRNA levels increase in the hypothalamus of 380 
primates and rodents during puberty, and Eap1 knockdown with siRNA causes delayed 381 
puberty and disrupted estrous cyclicity in a rodent model (Heger et al., 2007, Dissen et al., 382 
2012, Li and Li, 2017, Lomniczi et al., 2012, Xu and Li, 2016). Therefore, Eap1 383 
transcriptional activity facilitates the initiation of female puberty, in a manner that is 384 
independent of hypothalamic Kiss1 expression (Li and Li, 2017). Eap1 gene expression is 385 
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itself regulated by both activation by Ttf-1, and repression by Yy1 and a further transcriptional 386 
regulator Cux1 (Mueller et al., 2012). 387 
Enhanced at puberty 1: A very recent discovery is of the first human EAP1 mutations 388 
that appear to be causal for self-limited delayed puberty in two families (Mancini et al., 389 
2019). The affected individuals from these two families had classical clinical and 390 
biochemical features of self-limited delayed puberty, with presentation at more than 15.5 391 
years with delayed onset of Tanner stage 2 and delayed peak height velocity. Both probands 392 
had spontaneous pubertal development by the age of 18 years without testosterone therapy, 393 
thus excluding CHH. By whole exome sequencing of probands with familial delayed puberty 394 
two highly conserved variants - one in-frame deletion and one rare missense variant in EAP1 395 
- were identified. Using a luciferase reporter assay, EAP1 mutants showed a reduced ability 396 
to trans-activate the GnRH promoter compared to wild-type EAP1, due to reduced protein 397 
levels caused by the in-frame deletion and sub-cellular mis-location caused by the missense 398 
mutation. This study also demonstrated by chromatin immunoprecipitation that EAP1 399 
binding to the GnRH1 promoter increases in monkey hypothalamus at the onset of puberty. 400 
Polycomb complex genes: Furthermore, evidence from a recent study has emphasized 401 
the importance of the transcriptional control of the Kisspeptin gene Kiss1. This regulation by 402 
the polycomb complex proteins EED and Cbx7 is thought to be an important transcriptional 403 
repressive mechanism to prevent the premature onset of puberty (Lomniczi and Ojeda, 2016). 404 
In the latter stages of mid-childhood there is an increase in the methylation of the promoters 405 
of these genes, resulting in a reduction in expression, as well as a decrease in the binding of 406 
EED on the Kiss1 promoter. This inhibition of Kiss1 repression also correlates with reduced 407 
expression of transcription factors containing certain zinc finger motifs. Moreover, there is 408 
also reorganization of the chromatin status and changes in histone methylation to accompany 409 
the loss of these polycomb complex proteins from the Kiss1 promoter (Lomniczi et al., 2013). 410 
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Studies on both rats and goats also provide data on changes in histone acetylation and gene 411 
methylation resulting in alterations in gene expression during puberty (Morrison et al., 2014, 412 
Yang et al., 2016). 413 
Epigenetic mechanisms in the timing of puberty: There are a number of different 414 
epigenetic mechanisms that may have importance for the regulation of the pubertal timing, 415 
including imprinting. Imprinted genes are known to influence the timing of several key 416 
developmental stages in humans including weaning and adrenarche. In general, paternally 417 
expressed genes promote later childhood maturation and maternally expressed genes promote 418 
a more premature maturation (Peters, 2014). This holds true for two paternally inherited 419 
genes, MKRN3 and DLK1, which are associated with age at menarche in girls and voice-420 
breaking in boys from the GWAS discussed above (Day et al., 2017). Variants in both of 421 
these genes have been discovered in patients with familial central precocious pubertal timing, 422 
with paternally-inherited mutations leading to the expression of the phenotype (Abreu et al., 423 
2013, Dauber et al., 2017). MKRN3 is thought to contribute to the puberty brake restraining 424 
the HPG axis via inhibition of GnRH release. This gene encodes Makorin Ring finger protein 425 
3, a zinc finger protein containing a C3HC4 motif (known as a RING domain) associated 426 
with E3 ubiquitin ligase activity (Simon et al., 2016, Jong et al., 1999). Since MKRN3 427 
expression in the arcuate nucleus falls in murine models between birth and weaning, and in 428 
humans serum concentrations decline at puberty onset, it is thought to have an inhibitory 429 
effect on the GnRH network (Hagen et al., 2015, Busch et al., 2016). This supports the 430 
hypothesis that the onset of puberty is a consequence of the removal of gonadotropic axis 431 
repression. However, what is still unclear is where MKRN3 is placed in this hierarchy of gene 432 
regulators controlling kisspeptin levels. Very new data has demonstrated that knock-out of 433 
MKRN3  in pluripotent stem cells does not affect GNRH1-expression when these cells are 434 
later differentiated into neurons (Yellapragada et al., 2019). In terms of delayed puberty, 435 
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mutations in neither MKRN3 nor DLK1 genes have been described in human patients with 436 
these conditions.  437 
Imprinting and pubertal timing: Prader-Willi syndrome (PWS) is frequently caused 438 
by disorders of imprinting and is often associated with either absent or delayed puberty 439 
(Hirsch et al., 2015). In most patients with PWS the syndrome is due to a deletion of a cluster 440 
of imprinted genes (including MKRN3) on the paternally inherited copy of chromosome 15 441 
(paternal deletion), or by inheritance of both copies of this cluster from the mother (maternal 442 
uniparental disomy) (Butler, 2009). Precocious puberty is relatively uncommon in PWS (Lee 443 
and Hwang, 2013), but most individuals show some degree of pubertal failure, with one or a 444 
combination of an absent pubertal growth spurt, hypogonadotropic hypogonadism, 445 
cryptorchidism, underdeveloped genitalia, or primary amenorrhea (Crino et al., 2003). The 446 
probable explanation for the rarity of precocious puberty in individuals with PWS, despite the 447 
lack of MKRN3 expression, is the effects of other genes inactivated by the imprinting defect, 448 
in particular MAGEL2 (Kanber et al., 2009, de Smith et al., 2009). This points to a complex 449 
role for imprinted genes in the pubertal timing, with tissue type and developmental stage 450 
specific gene expression (Butler, 2009, Peters, 2014). 451 
Non-coding RNAs: Evidence from murine models has demonstrated that noncoding 452 
RNAs can act as epigenetic modulators of the timing of puberty. Specific microRNAs play a 453 
role in the epigenetic up-regulation of GnRH transcription during what is known in mice as 454 
“the critical period”, or infantile mini-puberty in humans (Messina et al., 2016). A key pair of 455 
microRNAs (miR-200 and mIR-155) are thought to regulate Gnrh1 expression, and to control 456 
the expression of two important transcriptional repressors of Gnrh1, Zeb-1 and Cebpb. There 457 
is an associated increase in the transcriptional activation of GnRH1 with a reduction in Zeb-1 458 
and Cebpb, the latter a nitric oxide-mediated repressor of Gnrh1 that acts both directly and 459 
through Zeb1. These changes lead to the up-regulation of Gnrh1 synthesis in GnRH neurons 460 
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(Messina et al., 2016). Moreover, miR-7a2 has been demonstrated to be essential for normal 461 
murine pituitary development and HPG function, with deletion in mice leading to 462 
hypogonadotropic infertility (Ahmed et al., 2017).  463 
Endocrine-disrupting chemicals: The increase of kisspeptin and GnRH expression in 464 
the hypothalamus at puberty is therefore the result of the actions of an intricate arrangement 465 
of repressing and activating transcription factors controlling Kiss1 and GnRH1 transcription, 466 
with these being themselves influenced by several epigenetic mechanisms including DNA 467 
methylation, histone modification and noncoding RNAs (Kurian et al., 2010, Lomniczi et al., 468 
2013, Messina et al., 2016, Toro et al., 2018). Moreover, these epigenetic mechanisms are 469 
possible facilitators of gene-environment interactions that also have influence on the 470 
hypothalamic regulation of puberty. A number of different sources of evidence have 471 
demonstrated that the brain epigenome at puberty is affected by environmental disturbances 472 
(Morrison et al., 2014). Endocrine-disrupting chemicals (EDCs), often found in products 473 
commonly used in the developed world, have been considered as a potential cause for 474 
pubertal timing disturbance for many years, with increasing concern among the lay 475 
population (Mouritsen et al., 2010). Many and varied substances have been identified as 476 
possible EDCs, such as polybrominated biphenyls, bisphenol A, atrazine (herbicides) and 477 
glyphosate, but also common medicines including paracetamol and betamethasone (Pinson et 478 
al., 2017, Drobna et al., 2018, Milesi et al., 2018, Parent et al., 2015). It has been observed 479 
that adolescents who have been exposed to the estrogenic insecticide DTT and then adopted 480 
internationally display early or precocious pubertal timing (Krstevska-Konstantinova et al., 481 
2001).  482 
The most important timing of EDC exposure for impact on pubertal timing was historically 483 
considered to be in late childhood, but there is now clear data that there may be prenatal and 484 
infantile origin of alterations in the timing of puberty. In utero exposure in males to EDCs, in 485 
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particular to phthalates, can result in under-masculinization of genitalia (Swan et al., 2005). 486 
Moreover, exposure of pregnant rodents to EDCs has been associated with epigenetic 487 
alterations in testis as well as other systemic effects. This together suggests that epigenetic 488 
changes in the fetal period are a potential mechanism for the hypothalamic effects of prenatal 489 
exposure to EDCs (Parent et al., 2015). These effects may manifest in pregnant rodents, their 490 
unborn fetus but also into the next two or more generations as well (Rissman and Adli, 2014).  491 
However, it is difficult to definitively demonstrate a mechanism of action for EDCs through 492 
the premature activation of the hypothalamic GnRH pulse generator. Recently, exposure of 493 
female mice to arsenic in utero was shown to alter the hypothalamic expression not only of 494 
GnRH and LH but also of their upstream transcriptional regulators, in particular Oct-2 and 495 
Ttf-1 (Li et al., 2018). Mice exposed to arsenic demonstrated precocious puberty with 496 
premature vaginal opening, a marker of the onset of puberty rodents. However, in most 497 
datasets it has been difficult to unpick the most likely differing, and possibly conflicting, 498 
influence of varying doses and combination of EDCs affecting estrogenic, androgenic or 499 
other pathways, and changes in effects depending on age and length of exposure (van den 500 
Driesche et al., 2015). 501 
 502 
Future Directions 503 
Over the last 2 years there have been very exciting developments in the understanding of the 504 
genetic basis of delayed puberty, particularly with respect to the transcriptional and 505 
epigenetic control of the GnRH “master switch”. We anticipate further discoveries in the near 506 
future that will help to elucidate these control mechanisms and better understand the genetic 507 
predisposition to familial delayed puberty and to conditions of functional hypogonadism. It 508 
 24 
is, of course, hoped that this knowledge can be rapidly translated into more efficient clinical 509 
diagnosis and management. 510 
 511 
Conclusion 512 
Puberty represents the remarkable transition from childhood to adult life with the attainment 513 
of reproduction and adult stature. The onset of puberty is elicited by the re-activation of the 514 
HPG axis, which is first functional in fetal life, through a rise in the pulsatile release of 515 
hypothalamic GnRH. Puberty can be deemed the consequence of a neurodevelopmental 516 
program, that begins prenatally but has many features in common with the postnatal 517 
development of other neuronal processes. However, its unique feature is as a functional 518 
system that lies dormant for most of childhood and then reactivates in the majority of the 519 
population within a short time window. This timing is controlled by genetic factors, relies 520 
upon an intact hormonal axis and influenced by the environment. It is thus not so surprising 521 
that pubertal delay and even aberrant pubertal development are not infrequent human 522 
pathologies.  523 
The genetic regulators that determine timing of puberty in the general population, a trait that 524 
follows a skewed near-normal distribution, have relevance to conditions of delayed and even 525 
aberrant pubertal onset (Figure 5). There is also overlap between those pathways found to be 526 
defective in self-limited delayed, precocious and absent puberty conditions, with the 527 
phenotype varying dependent on the impact of the gene defect and mutational burden. So 528 
whilst there are shared pathogenic mechanisms between these conditions, there is also much 529 
heterogeneity in the genetic changes responsible for delayed puberty. Defects in GnRH 530 
neuronal development and function, transcriptional regulation of the HPG axis, epigenetic 531 
mechanisms including DNA methylation, histone modification and noncoding RNAs, and 532 
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metabolic and energy homeostatic derangements, can all lead to the final common pathway 533 
of delayed puberty. Moreover, these genomic regulators can exert their influence in fetal life, 534 
during postnatal development and in mid-childhood, all having an effect in adolescence on 535 
pubertal timing.  536 
Genetic testing may allow the translation of this understanding to benefit patient care in the 537 
future:  as a diagnostic tool for the investigation of delayed puberty, by informing the natural 538 
history of the condition, possible inheritance in the individual’s family and optimization of 539 
treatment. Rapid and accurate diagnostic testing in clinic would greatly improve patient care 540 
and most likely represent a significant advantage in terms of health economics. 541 
 542 
 543 
Acknowledgements 544 
SRH is funded by the NIHR (CL-2017-19-002), The Rosetrees Trust (M222-F1), and 545 
supported by the Academy of Medical sciences, Wellcome Trust, Medical Research Council, 546 
British Heart Foundation, Arthritis Research UK and Diabetes UK through the clinical 547 
lecturers scheme (SGL019\1043). 548 
  549 
 26 
Figure and Figure Legends 550 
 551 
Figure 1 – Schematic showing the normal distribution of timing of pubertal onset in the 552 
general population, with definitions of precocious and delayed being < or > 2 standard 553 
deviations from the mean age respectively. Top right panel shows an example of a male 554 
puberty normogram demonstrating arrested puberty at G3. G – genital stage (Tanner); B – 555 
breast stage (Tanner); GWAS – genome wide association studies; SD – standard deviation 556 
 557 
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 558 
Figure 2 – Example pedigrees demonstrating the typical autosomal dominance inheritance 559 
pattern seen in self-limited delayed puberty (pedigrees 2 and 4), including bilineal inheritance 560 
(shown in pedigree 1), and incomplete penetrance (pedigree 3). Black circles/squares – 561 
delayed puberty; clear circles/squares – normal timing of puberty; grey circles/squares – 562 
timing of puberty not known. 563 
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 565 
Figure 3  – Genetic regulators in the trans-synaptic and glial control of GnRH neurons at the 566 
onset of puberty, original idea from (Ojeda et al., 2006) and adapted from (Howard, 2018) 567 
under the CC-BY licence. + represents an activating signal, - represents a repressing signal. 568 
Red circles highlight genes, mutations in which have been shown to affect pubertal timing. 569 
WAT – white adipose tissue; glu – glutamate; gluR – glutamate receptor; KNDY – see text. 570 
 571 
Upstream Controlling Genes
Transcriptional regulators e.g.      EAP1,   Oct2 
GnRH 
Neurons
ñSynchronised pulsatile 
release of  GnRH
Functional Integration of  Neuronal and Glial Networks
PGER
FGFR
IGFR
TGFBR
GluR
GABAR
OPR
Glial Cell
GluR
Neuronal cells

Prepro
ENK
Neuron
GABA
Neuron (+)
(+)
(+)
(+)
(-)
(-)(+)
KNDY
Neuron
GluR(-?)
GluR
Glu
Neuron
GABAR
(-)(-)
(+?)
(+)
(+)
(+)
TACR3
PUBERTYGNRHR
KISS1R
(+)
Leptin 
(WAT)
LEPR
GABAR
 29 
 572 
Figure 4 – Schematic of the mechanism by which IGSF10 mutations lead to delayed puberty. 573 
Reduced levels of IGSF10 expression during embryogenesis in the corridor of nasal 574 
mesenchyme from the vomeronasal organ to the olfactory bulbs result in delayed migration 575 
of GnRH neurons to the hypothalamus. This leads to a phenotype of delayed puberty first 576 
evident in adolescence, due to abnormalities of the GnRH neuroendocrine network. Adapted 577 
from doi.10.1210/er.2018-00248. 578 
 579 
 580 
 581 
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Figure 5 – Established genetic basis of common genetic variants of pubertal timing from 582 
genome wide association studies (GWAS), conditions of GnRH deficiency (CHH and KS), 583 
precocious puberty and delayed puberty and their overlap. Activating and inactivating 584 
mutations in KISS1 and KISS1R cause the opposite phenotypes, precocious puberty and 585 
CHH, respectively. Bold circles highlight those genes, mutations in which have been 586 
identified in familial delayed puberty. Adapted from (Howard, 2018) under the CC-BY 587 
licence. 588 
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